文献速递胸部肿瘤

简报:度伐利尤单抗联合曲美木单抗在程序性死亡受体(配体)1单药治疗经治的晚期非小细胞肺癌中的安全性与抗肿瘤活性:1b期临床试验结果

Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.
PubMed 文献 · J Thorac Oncol · 2023-05-04

这项1b期研究评估度伐利尤单抗联合曲美木单抗用于以抗PD-(L)1单药为最近治疗线的晚期非小细胞肺癌成人患者。PD-(L)1难治组客观缓解率为5.3%,PD-(L)1复发组为0%。联合方案安全性可控,但PD-(L)1治疗失败后该联合方案无效。

要点

  • PD-(L)1难治组客观缓解率为5.3%(1例完全缓解、1例部分缓解),PD-(L)1复发组为0%。
  • 最常见治疗相关不良事件:PD-(L)1难治组为疲乏(26.3%),PD-(L)1复发组为腹泻(27.5%)。
  • 3至4级治疗相关不良事件发生于22例患者;联合方案安全性可控,但PD-(L)1治疗失败后无效。

核心结论

  • 度伐利尤单抗联合曲美木单抗安全性可控,但在PD-(L)1治疗失败后该联合方案无效。

研究设计与样本

  • 1b期临床试验(NCT02000947),2013年10月25日至2019年9月17日入组PD-(L)1复发或难治的晚期非小细胞肺癌患者。
  • 度伐利尤单抗20 mg/kg联合曲美木单抗1 mg/kg静脉给药,每4周一次共4剂,随后度伐利尤单抗单药每4周一次最多9剂,治疗最长12个月或至疾病进展。
  • PD-(L)1难治组38例,PD-(L)1复发组40例接受治疗。

主要发现

  • PD-(L)1难治组客观缓解率为5.3%(1例完全缓解、1例部分缓解),PD-(L)1复发组为0%。
  • 最常见治疗相关不良事件:PD-(L)1难治组为疲乏(26.3%),PD-(L)1复发组为腹泻(27.5%)。
  • 3至4级治疗相关不良事件发生于22例患者。
  • 中位随访时间PD-(L)1难治组为43.6个月,PD-(L)1复发组为41.2个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Although first-line immunotherapy approaches are standard, in patients with non-small cell lung cancer (NSCLC) previously treated with programmed cell death protein-1 or programmed death-(ligand)1 (PD-[L]1) inhibitors, the activity of combined CTLA-4 plus PD-(L)1 inhibition is unknown. This phase 1b study evaluated the safety and efficacy of durvalumab plus tremelimumab in adults with advanced NSCLC who received anti-PD-(L)1 monotherapy as their most recent line of therapy. METHODS: Patients with PD-(L)1-relapsed or refractory NSCLC were enrolled between October 25, 2013, and September 17, 2019. Durvalumab 20 mg/kg plus tremelimumab 1 mg/kg was administered intravenously every 4 weeks for four doses, followed by up to nine doses of durvalumab monotherapy every 4 weeks for up to 12 months of treatment or disease progression. Primary end points included safety and objective response rate (ORR) on the basis of Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review; secondary end points were ORR on the basis of RECIST v1.1 per investigator; duration of response, disease control, and progression-free survival on the basis of RECIST v1.1 per blinded independent central review and investigator; and overall survival. CLINICALTRIALS: gov identifier: NCT02000947. RESULTS: PD-(L)1-refractory (n = 38) and PD-(L)1-relapsed (n = 40) patients were treated. The most common treatment-related adverse events were fatigue (26.3%, PD-(L)1-refractory patients) and diarrhea (27.5%, PD-(L)1-relapsed patients). Grade 3 to 4 treatment-related adverse events occurred in 22 patients. Median follow-up duration was 43.6 months for PD-(L)1-refractory patients and 41.2 months for PD-(L)1-relapsed patients. The ORR was 5.3% for PD-(L)1-refractory patients (one complete response, one partial response) and 0% for PD-(L)1-relapsed patients. CONCLUSIONS: Durvalumab plus tremelimumab had a manageable safety profile, but the combination did not have efficacy after PD-(L)1 treatment failure.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Garon EB, Spira AI, Goldberg SB, et al. Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial. J Thorac Oncol. 2023. PMID: 37146752. doi:10.1016/j.jtho.2023.04.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。